Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822688 · ClinicalTrials.gov registry record
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 141
- Enrollment target
NCT04822688: Completed study, sponsored by Thomas Jefferson University.
NCT04822688 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04822688 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.
Primary Outcome
This will be determined for each sample. Cell yield data is measured in 106and is assumed to be normally distributed. Summary statistics of mean, standard deviation, 95% confidence interval and range will be reported.
Interventions
- PROCEDURE Biospecimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2025-06-30 |
What the finished NCT04822688 record still lists
NCT04822688 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT04822688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04822688 about?
NCT04822688 is a clinical study titled "Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues". This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform f...
What is the current status of trial NCT04822688?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2021-02-03. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04822688?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04822688?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI